Brussels, 23/10/2014 (Agence Europe) - Under certain conditions, pharmaceutical companies may challenge decisions to authorise the marketing of a generic version of a drug it produces, the Court of Justice ruled in a verdict (case C-104/13) returned on Thursday 23 October.
Although the directive instituting the Community code on drugs for human usage (2001/83/EC) defines what a generic drug is and how it can be sold, it provides no rights of recourse for the holders of reference drugs....